...
首页> 外文期刊>Current paediatrics >Paediatric interstitial lung disease (PILD)-An update
【24h】

Paediatric interstitial lung disease (PILD)-An update

机译:小儿间质性肺疾病(PILD)-更新

获取原文
获取原文并翻译 | 示例
           

摘要

Interstitial lung disease affects approximately 1 in 100,000 infants and children. The aetiology of as many as 40-50% of cases remains unknown at present. Recent advances in the understanding of surfactant genetics and the description of specific ultrastructural anomalies have advanced our knowledge of the underlying pathophysiology and the genetics of familial cases. Investigations should aim to exclude known underlying causes. A computed tomography (CT) examination is useful in assessing parenchymal involvement, but the lung biopsy remains most useful when the aetiology is unclear. There are no controlled trials of treatment because of the relatively small numbers of patients involved. Sixty-five percent of patients are likely to respond well to corticosteroids with or without hydroxychloroquine. About 10-15% will need continuing treatment over many months or years. The mortality rate among those with idiopathic disease is 15%.
机译:间质性肺疾病影响约100,000个婴儿和儿童中的1个。目前尚不清楚多达40-50%的病例的病因。对表面活性剂遗传学的了解和对特定超微结构异常的描述的最新进展,使我们对潜在的病理生理学和家族病例的遗传学有了更深入的了解。调查应旨在排除已知的根本原因。计算机断层扫描(CT)检查可用于评估实质侵犯程度,但是当病因不清楚时,肺活检仍是最有用的检查方法。由于涉及的患者相对较少,因此没有对照治疗试验。 65%的患者可能对有或没有羟氯喹的皮质类固醇激素反应良好。大约10-15%的患者将需要在数月或数年内继续治疗。特发性疾病患者的死亡率为15%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号